HMG-CoA reductase inhibitors improve acute ischemic stroke outcome

Stroke

Volumn 36, Issue 6, 2005, Pages 1298-1300

  Moonis, Majaz ^a,c   Kane, Kevin ^a   Schwiderski, Ute ^b   Sandage, Bobby W ^b   Fisher, Marc ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Indevus Pharmaceuticals Inc   (United States)

^c University of Massachusetts   (United States)

Author keywords

Ischemia; Stroke; Stroke outcome

Indexed keywords

ANTIHYPERTENSIVE AGENT; CITICOLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATINE DERIVATIVE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; PROBABILITY; RANKIN SCALE; RECURRENT DISEASE; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT OUTCOME;

AGED; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RECURRENCE; REGRESSION ANALYSIS; RISK; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 20444375418     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000165920.67784.58     Document Type: Article

References (9)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326):7-22.
3. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthatase and protects from ischemic stroke in mice. Brain Research. 2002;942(1-2):23-30.
4. Aronow HD. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice. Curr Control Trials Cardiovasc Med. 2002;3:3.
5. Ovbiagele B, Saver JL, Fredieu A, Suzuki S, Selco S, Rajajee V, McNair N, Razinia T, Kidwell CS. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke. 2004;35:2879-2883.
6. Zhang R, Zhang L, Zhang Z, Wang Y, Lu M, Lapointe M, Chopp M. A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann Neurol. 2001;50:602-611.
7. Chen J, Li Y, Zhang ZG, Wang L, Wang Y, Jiang H, Lu M, Katakowski M, Feldkamp CS, Chopp M. HMG-CoA reductase inhibitor induces angiogenesis, neurogenesis, synaptogenesis and improves functional outcome after stroke. Ann Neurol. 2003;53:743-751.
8. Di Napoli M, Papa F. Inflammation, statins, and outcome after ischemic stroke. Stroke. 2001;32:2446-2447.
9. Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, Cocho D, Roquer J, rodriguez A, Garcia MD, Molina-Parcel L, Diaz-Manera J, Marti-Vilalta JL. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke. 2004;35:1117-1121.